Published • loading... • Updated
Palatin Technologies Announces Closing of Reduced Public Offering
- Palatin Technologies, a biopharmaceutical company, announced on May 8, 2025, from Cranbury, N.J., the closing of a reduced public offering.
- The closing occurred after the SEC declared the offering effective on May 6, 2025, involving investments from qualified institutional and accredited buyers and comprising common stock and warrants.
- The offering included 7.3 million common shares along with Series F warrants exercisable at $0.30 each, all sold together at a combined price of $0.15 per unit.
- Palatin secured roughly $1.1 million in gross proceeds from the offering and plans to allocate the net funds mainly toward operational expenses and overall corporate needs.
- This financing supports Palatin’s development of targeted, receptor-specific medicines modulating melanocortin receptors to treat diseases with unmet medical needs.
Insights by Ground AI
52 Articles
52 Articles
Palatin Technologies Announces Closing of Reduced Public Offering - PressReach
Company Transitioned onto the OTC Pink CRANBURY, N.J., May 8, 2025 /PRNewswire/ — Palatin Technologies, Inc. (OTC PINK: PTNT) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consi…
Coverage Details
Total News Sources52
Leaning Left6Leaning Right9Center12Last UpdatedBias Distribution45% Center
Bias Distribution
- 45% of the sources are Center
45% Center
L 22%
C 45%
R 33%
Factuality
To view factuality data please Upgrade to Premium
